- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00453089
VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women
February 6, 2012 updated by: Bionovo
A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH > 5.0 and > 20% parabasal vaginal epithelial cells.
Study Overview
Detailed Description
Primary Aims:
- the optimal dose of VG101 based on the highest of 4 proposed dose levels that is not associated with unacceptable toxicity during 12 weeks of treatment. Toxicity will be based on National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 3. Unacceptable toxicity will be defined as the occurrence of any Grade 3, 4, of 5 toxicity that is possibly or probably associated with study drug or any other unacceptable toxicity as determined by the Data and Safety Monitoring Board.
- Specific potential adverse effects of VG101
Secondary Aims:
the preliminary efficacy of VG101 to:
- relieve vulvar and/or vaginal dryness,
- relieve vulvar and/or vaginal irritation
- relieve vulvar and/or vaginal itching
- relieve vulvar and/or vaginal discharge
- relieve dyspareunia
- improve sexual function
- relieve dysuria
- reduce frequency of urinary incontinence
- improve quality of life
- improve the physical examination assessment of vaginal atrophy
- reduce vaginal fluid pH
- improve the proportion of superficial vaginal epithelial cells
- participant adherence to VG101 administration
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama, Birmingham
-
Contact:
- Holly Richter, M.D., PhD
- Phone Number: 205-934-3180
- Email: hrichter@uab.edu
-
Principal Investigator:
- Holly Richter, M.D., PhD
-
-
California
-
San Francisco, California, United States, 94115
- University of California, San Francisco
-
Contact:
- Deborah Grady, M.D., MPH
- Phone Number: 415-353-9748
- Email: Deborah.Grady@ucsf.edu
-
Principal Investigator:
- George Sawaya, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women between the ages of 45 and 65
- Postmenopausal documented by: (a) at least one year of amenorrhea; (b) 6- 12 months of amenorrhea with serum FSH > 40 IU/ml; (c) 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, or (d) hysterectomy with serum FSH levels > 40 IU/ml.
Self-report at least one moderate to severe symptom of vulvar or vaginal atrophy from the following list:
- Vaginal dryness (none, mild, moderate or severe)
- Vaginal and/or vulvar discomfort (none, mild, moderate, severe)
- Vaginal and/or vulvar irritation (none, mild, moderate, severe)
- Vaginal itching (none, mild, moderate, severe)
- Vaginal pain associated with sexual activity (none, mild, moderate or severe)
- < 5% superficial cells on vaginal cytologic smear.
- Vaginal pH >5.0
- Willing to use an intravaginal cream containing Chinese herbs for the treatment of vaginal symptoms.
- Provide informed consent.
Exclusion Criteria:
- History of breast, uterine or ovarian cancer or melanoma.
- Abnormal mammogram or breast examination within the last 9 months suggestive of cancer.
- Abnormal Pap smear or pelvic examination within the last 9 months suggestive of cancer.
- Any uterine or vaginal bleeding within the six months prior to enrollment (except following the screening Pap smear).
- Double-wall endometrial thickness that exceeds 5 mm measured on transvaginal ultrasound.
- Pregnant or lactating.
- Use of any vaginal moisturizer (Replens, KY Silk-E, Astroglide Silken Secret, Senselle) within 30 days of screening.
- Use of any oral, transdermal, vaginal, or systemic estrogen or estrogen/progestin product within 30 days of screening.
- Use of raloxifene, tamoxifen or aromatase inhibitors within 12 weeks of screening.
- Current urinary tract infection (dipstick urinalysis positive for leukocyte estrace, nitrates or blood)
- History of cardiovascular disease.
- History of venous thromboembolic disease.
- Use of another investigational agent within 12 weeks of screening.
- Any medical or psychiatric condition that, in the investigator's opinion, would preclude the participant from completing questionnaires or measures, adhering to the protocol or completing the trial, including limited English literacy, severe illness, plans to move, substance abuse, significant psychiatric problems, or dementia.
- No access to a telephone
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in self-reported symptoms of vaginal atrophy from baseline to 12 weeks
Time Frame: 4 and 12 weeks
|
4 and 12 weeks
|
Change in percent superficial vaginal epithelial cells from baseline 12 weeks
Time Frame: 4 and 12 weeks
|
4 and 12 weeks
|
Change in the pH of vaginal secretions from baseline to 12 weeks
Time Frame: 4 and 12 weeks
|
4 and 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mary Tagliaferri, MD, Bionovo, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Anticipated)
June 1, 2013
Study Completion (Anticipated)
August 1, 2013
Study Registration Dates
First Submitted
March 26, 2007
First Submitted That Met QC Criteria
March 27, 2007
First Posted (Estimate)
March 28, 2007
Study Record Updates
Last Update Posted (Estimate)
February 8, 2012
Last Update Submitted That Met QC Criteria
February 6, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VG-101-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Atrophy
-
Petra LarmoTurun Gynekologikeskus Oy; Tekes - The Finnish Funding Agency for Technology...CompletedVaginal Atrophy | Vaginal Dryness | Vulvar Atrophy | Vulvar DrynessFinland
-
Rajavithi HospitalTerminatedVaginal Atrophy | Oxytocin Gel | Postmenopausal Women | Vaginal Maturation IndexThailand
-
Sun Pharmaceutical Industries LimitedTerminated
-
Bitop AGCompleted
-
University of Texas Southwestern Medical CenterAmerican Society for Aesthetic Plastic SurgeryCompleted
-
Dr. August Wolff GmbH & Co. KG ArzneimittelproDERM GmbHCompleted
-
National and Kapodistrian University of AthensIRCCS San RaffaeleUnknown
-
Syneron MedicalUnknownVaginal AtrophyUnited States
-
Herbarium Laboratorio Botanico LtdaNot yet recruiting
-
Italfarmaco S.ACompleted